Quick Answer
VACCINEX, INC. reported Long Term Debt of $0.00 for the year ending 2024.
- VACCINEX, INC. showed a decrease of -100.0% in Long Term Debt from 2023 to 2024.
- This data is from VACCINEX, INC.'s annual report (Form 10-K), filed with the SEC on April 15, 2025.
- XBRL data for this metric is available from 2020 to 2024 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2020: $1.13 million | Q3 2020: $1.13 million | Q1 2021: $1.13 million | Q2 2021: $1.13 million | Q3 2021: $1.13 million | Q1 2022: $156.0 thousand | Q2 2022: $138.0 thousand | Q3 2022: $119.0 thousand | Q1 2023: $82.0 thousand | Q2 2023: $63.0 thousand | Q3 2023: $44.0 thousand | Q1 2024: $6.0 thousand.
- Over the full 5 years of available data (2020 to 2024), VACCINEX, INC.'s Long Term Debt has declined by 100.0%.
- Historical annual values: Fiscal year 2024: $0.00 | Fiscal year 2023: $26.0 thousand | Fiscal year 2022: $101.0 thousand | Fiscal year 2021: $175.0 thousand | Fiscal year 2020: $1.13 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: